Key result
Low-dose aspirin significantly increased mean gestational age at delivery compared to placebo (38.2 vs. 36.8 weeks) in women with high-risk pregnancies.
Why the study?
Preeclampsia is a major cause of maternal and neonatal illness and death, prompting an evaluation of the efficacy of low-dose aspirin for its prevention in high-risk pregnancies.
Does low-dose aspirin 81 mg daily prevent preeclampsia in high-risk pregnancies?
Population
165 pregnant women at Shalamar Hospital, Lahore
Comparison
Daily 81 mg low-dose aspirin vs identical-looking placebo
Design
Randomized control trial
Authors
Loading...
Supports low-dose aspirin initiation at 12-16 weeks in high-risk pregnancies; confirms preeclampsia prevention in this RCT.
RCT (n=165)
Blinded (identical-looking placebo)
Randomly assigned
No
Does low-dose aspirin 81 mg daily prevent preeclampsia in high-risk pregnancies?
Absolute Event Rate: 38.2% vs 36.8%
Low-dose aspirin (81 mg daily) initiated between 12-16 weeks of gestation significantly reduces the incidence of preeclampsia and improves neonatal outcomes in high-risk pregnancies.
Zulfiqar et al. (2025) conducted an RCT in High-risk pregnancy (n=165). Low-dose aspirin vs. Placebo was evaluated on Gestational age at delivery. Low-dose aspirin significantly increased mean gestational age at delivery compared to placebo (38.2 vs. 36.8 weeks) in women with high-risk pregnancies.